Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial

Psychiatry Research

Volumn 169, Issue 2, 2009, Pages 118-123

  Kang, Eun Ho ^a   Lee, In Soo ^b   Chung, Sang Keun ^c   Lee, Sang Yeol ^d   Kim, Eui Jung ^e   Hong, Jin Pyo ^f   Oh, Kang Seob ^a   Woo, Jong Min ^g   Kim, Seonwoo ^h   Park, Joo Eon ⁱ   Yu, Bum Hee ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Department of Psychiatry   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

^d Wonkwang University   (South Korea)

^e Ewha Womans University School of Medicine   (South Korea)

^f Asan Medical Center   (South Korea)

^g Inje University College of Medicine   (South Korea)

^h Samsung Medical Center   (South Korea)

ⁱ Keyo Hospital   (South Korea)

Author keywords

Major depressive disorder; Mirtazapine; Somatic symptom; Treatment response; Venlafaxine

Indexed keywords

MIRTAZAPINE; VENLAFAXINE;

ADULT; AGED; ANXIETY; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; FACE EDEMA; FEMALE; HUMAN; HYPERHIDROSIS; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEMORY DISORDER; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PSYCHOSOMATIC DISORDER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SYMPTOM CHECKLIST 90; SYMPTOMATOLOGY; URINARY DYSFUNCTION; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHI-SQUARE DISTRIBUTION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SOMATOSENSORY DISORDERS;

EID: 69649099378     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.06.021     Document Type: Article

References (33)

1. Bomholt S.F., Mikkelsen J.D., and Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 48 (2005) 252-263
2. Buysse D.J., Reynolds III C.F., Monk T.H., Berman S.R., and Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research 28 (1989) 193-213
3. Delgado P.L. Common pathways of depression and pain. Journal of Clinical Psychiatry 65 Suppl 12 (2004) 16-19
4. Derogatis L.R. Symptom Checklist-90-Revised (SCL-90-R) Manual I (1977), Clinical Psychometric Research Unit, Johns Hopkins University, Baltimore
5. Entsuah R. Venlafaxine vs SSRIs: comparison of somatic symptom resolution. World Journal of Biological Psychiatry 5 (2004) 11
6. Fava M. Somatic symptoms, depression, and antidepressant treatment. Journal of Clinical Psychiatry 63 (2002) 305-307
7. Fava M. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. Journal of Clinical Psychiatry 64 Suppl 13 (2003) 26-29
8. Fava M. Depression with physical symptoms: treating to remission. Journal of Clinical Psychiatry 64 Suppl 7 (2003) 24-28
9. Fawcett J., and Barkin R.L. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. Journal of Affective Disorder 51 (1998) 267-285
10. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders (1996), Biometrics Research, New York State Psychiatric Institute, New York
11. Fishbain D. Evidence-based data on pain relief with antidepressants. Annals of Medicine 32 (2000) 305-316
12. Freynhagen R., Muth-Selbach U., Lipfert P., Stevens M.F., Zacharowski K., Tolle T.R., and von Giesen H.J. The effect of mirtazapine in patients with chronic pain and concomitant depression. Current Medical Research Opinion 22 (2006) 257-264
13. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 32 (1959) 50-55
14. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 23 (1960) 56-62
15. Jann M.W., and Slade J.H. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy 27 (2007) 1571-1587
16. Katon W., Kleinman A., and Rosen G. Depression and somatization: a review. Part I. American Journal of Medicine 72 (1982) 127-135
17. Keller M.B., and Berndt E.R. Depression treatment: a lifelong commitment?. Psychopharmacology Bulletin 36 Suppl 2 (2002) 133-141
18. Kroenke K., and Price R.K. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Archives of Internal Medicine 153 (1993) 2474-2480
19. Kroenke K., Spitzer R.L., Williams J.B.W., Linzer M., Hahn S.R., deGruy III F.V., and Brody D. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Archives of Family Medicine 3 (1994) 774-779
20. Kroenke K., Spitzer R.L., and Williams J.B.W. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosomatic Medicine 64 (2002) 258-266
21. Kroenke K., Messina III N., Benattia I., Graepel J., and Musgnung J. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. Journal of Clinical Psychiatry 67 (2006) 72-80
22. O'Malley P.G., Jackson J.L., Santoro J., Tomkins G., Balden E., and Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. Journal of Family Practice 48 (1999) 980-990
23. Papakostas G.I., Petersen T., Denninger J., Sonawalla S.B., Mahal Y., Alpert J.E., Nierenberg A.A., and Fava M. Somatic symptoms in treatment-resistant depression. Psychiatry Research 118 (2003) 39-45
24. Ruoff G.E. Depression in the patient with chronic pain. Journal of Family Practice 43 (1996) S25-S33 discussion S34
25. Samborski W., Lezanska-Szpera M., and Rybakowski J.K. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 37 (2004) 168-170
26. Sayar K., Aksu G., Ak I., and Tosun M. Venlafaxine treatment of fibromyalgia. Annals of Pharmacotherapy 37 (2003) 1561-1565
27. Schreiber S., Bleich A., and Pick C.G. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects-a possible opioid involvement in severe depression?. Journal of Molecular Neuroscience 18 (2002) 143-149
28. Seemüller F., Riedel M., Wickelmaier F., Adli M., Mundt C., Marneros A., Laux G., Bender W., Heuser I., Zeiler J., Gaebel W., Jager M., Moller H.J., and Henkel V. Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity. Journal of Affective Disorders 108 (2008) 271-278
29. Simon G.E., VonKorff M., Piccinelli M., Fullerton C., and Ormel J. An international study of the relation between somatic symptoms and depression. New England Journal of Medicine 341 (1999) 1329-1335
30. Smith A.J. The analgesic effects of selective serotonin reuptake inhibitors. Journal of Psychopharmacology 12 (1998) 407-413
31. Stahl S.M. The psychopharmacology of painful physical symptoms in depression. Journal of Clinical Psychiatry 63 (2002) 382-383
32. Wellington K., and Perry C.M. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 15 (2001) 643-669
33. Wessely S., and Hindmarch I. Taking the pain out of depression: dual action antidepressants in the relief of pain in depression, fibromyalgia and other chronic pain syndromes. Human Psychopharmacology 19 Suppl 1 (2004) S1-2